BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 36290878)

  • 21. A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus.
    Wolfson AH; Brady MF; Rocereto T; Mannel RS; Lee YC; Futoran RJ; Cohn DE; Ioffe OB
    Gynecol Oncol; 2007 Nov; 107(2):177-85. PubMed ID: 17822748
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of multimodal adjuvant therapy for FIGO I-II carcinosarcoma of the uterus: a systematic review.
    van der Horst RL; van der Hel O; Lutgens L; van der Aa M; Slangen B; Kruitwagen R; Lalisang RI
    Crit Rev Oncol Hematol; 2022 Jul; 175():103701. PubMed ID: 35533817
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of adjuvant therapy on the prognosis in stage I/II uterine carcinosarcoma: A meta-analysis.
    Zhao F; Tan P; Wang C; Ji X; Chen A
    J Obstet Gynaecol Res; 2021 Jul; 47(7):2473-2480. PubMed ID: 33913222
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Patterns of care, predictors, and outcomes of chemotherapy in elderly women with early-stage uterine carcinosarcoma: a population-based analysis.
    Garg G; Yee C; Schwartz K; Mutch DG; Morris RT; Powell MA
    Gynecol Oncol; 2014 May; 133(2):242-9. PubMed ID: 24561247
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Effect of Adjuvant Pelvic Radiotherapy on Distant Metastasis for Uterine Carcinosarcoma.
    Eng NL; Rana SR; Hall KL; Eng TY
    Am J Clin Oncol; 2021 Apr; 44(4):169-173. PubMed ID: 33481373
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adjuvant chemotherapy in uterine carcinosarcoma: Comparison of a doublet and a triplet chemotherapeutic regimen.
    Maheshwari U; Rajappa SK; Talwar V; Goel V; Dash PK; Sharma M; Goyal P; Jain P; B Koyyala VP; Doval DC
    Indian J Cancer; 2021; 58(2):179-184. PubMed ID: 33753600
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Review of Recommended Treatment of Uterine Carcinosarcoma.
    Menczer J
    Curr Treat Options Oncol; 2015 Nov; 16(11):53. PubMed ID: 26374341
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Is minimally invasive surgery for clinical stage I uterine carcinosarcoma safe?
    Sinha R; Nizam A; Shan W; Shih KK; Frimer M; Sakaris A; Goldberg GL
    J Robot Surg; 2022 Aug; 16(4):943-949. PubMed ID: 34716874
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adjuvant Treatment Modalities, Prognostic Factors, and Outcome of the Uterine Carcinosarcoma.
    Kahramanoglu I; Demirkiran F; Turan H; Bese T; Cebi S; Ilvan S; Arvas M
    J Obstet Gynaecol Can; 2021 Jan; 43(1):34-42. PubMed ID: 33041218
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical significance of radiotherapy in patients with primary uterine carcinosarcoma: a multicenter retrospective study (KROG 13-08).
    Cha J; Kim YS; Park W; Kim HJ; Kim JY; Kim JH; Kim J; Yoon WS; Kim JW; Kim YB
    J Gynecol Oncol; 2016 Nov; 27(6):e58. PubMed ID: 27550404
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Uterine adenosarcoma with sarcomatous overgrowth versus uterine carcinosarcoma: comparison of treatment and survival.
    Krivak TC; Seidman JD; McBroom JW; MacKoul PJ; Aye LM; Rose GS
    Gynecol Oncol; 2001 Oct; 83(1):89-94. PubMed ID: 11585418
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tumor characteristics and outcome of uterine carcinosarcoma in women aged ≥80 years.
    Matsuo K; Ross MS; Yunokawa M; Johnson MS; Machida H; Omatsu K; Klobocista MM; Im DD; Satoh S; Baba T; Ikeda Y; Bush SH; Hasegawa K; Blake EA; Takekuma M; Shida M; Nishimura M; Adachi S; Pejovic T; Takeuchi S; Yokoyama T; Ueda Y; Iwasaki K; Miyake TM; Yanai S; Nagano T; Takano T; Shahzad MM; Ueland FR; Kelley JL; Roman LD
    Surg Oncol; 2019 Jun; 29():25-32. PubMed ID: 31196490
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic factors impacting survival in early stage uterine carcinosarcoma.
    Kurnit KC; Previs RA; Soliman PT; Westin SN; Klopp AH; Fellman BM; Lu KH; Ramondetta LM; Fleming ND
    Gynecol Oncol; 2019 Jan; 152(1):31-37. PubMed ID: 30414738
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The impact of adjuvant radiation therapy on survival in women with uterine carcinosarcoma.
    Clayton Smith D; Kenneth Macdonald O; Gaffney DK
    Radiother Oncol; 2008 Aug; 88(2):227-32. PubMed ID: 18160157
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chemoradiation Versus Chemotherapy in Uterine Carcinosarcoma: Patterns of Care and Impact on Overall Survival.
    Odei B; Boothe D; Suneja G; Werner TL; Gaffney DK
    Am J Clin Oncol; 2018 Aug; 41(8):784-791. PubMed ID: 28121642
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Patterns of failure for conservatively managed surgical stage I uterine carcinosarcoma: implications for adjuvant therapy.
    Leath CA; Numnum TM; Kendrick JE; Frederick PJ; Rocconi RP; Conner MG; Straughn JM
    Int J Gynecol Cancer; 2009 Jul; 19(5):888-91. PubMed ID: 19574779
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Optimal cytoreductive surgery in patients with advanced uterine carcinosarcoma: A multi-institutional retrospective study from the Japanese gynecologic oncology group.
    Harano K; Hirakawa A; Yunokawa M; Nakamura T; Satoh T; Nishikawa T; Aoki D; Ito K; Ito K; Nakanishi T; Susumu N; Takehara K; Watanabe Y; Watari H; Saito T
    Gynecol Oncol; 2016 Jun; 141(3):447-453. PubMed ID: 27072806
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Wilms' tumor 1 protein and estrogen receptor beta expression are associated with poor outcomes in uterine carcinosarcoma.
    Guntupalli SR; Cao D; Shroff R; Gao F; Menias C; Stewart Massad L; Powell MA; Mutch DG; Thaker PH
    Ann Surg Oncol; 2013 Jul; 20(7):2373-9. PubMed ID: 23344579
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combination of adjuvant chemotherapy and radiotherapy is associated with improved survival at early stage type II endometrial cancer and carcinosarcoma.
    Sozen H; Çiftçi R; Vatansever D; Topuz S; Iyibozkurt AC; Bozbey HU; Yaşa C; Çali H; Yavuz E; Kucucuk S; Aydiner A; Salihoglu Y
    Aust N Z J Obstet Gynaecol; 2016 Apr; 56(2):199-206. PubMed ID: 26890292
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic factors for disease-free and overall survival of patients with uterine carcinosarcoma.
    Şükür YE; Taşkın S; Varlı B; Ateş C; Güngör M; Ortaç F
    Int J Clin Oncol; 2018 Feb; 23(1):114-120. PubMed ID: 28836024
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.